MYELOFIBROSIS (MF)
Clinical trials for MYELOFIBROSIS (MF) explained in plain language.
Never miss a new study
Get alerted when new MYELOFIBROSIS (MF) trials appear
Sign up with your email to follow new studies for MYELOFIBROSIS (MF), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug aims to stop anemia after stem cell transplants
Disease control Not yet recruitingThis study tests whether the drug luspatercept can prevent severe anemia (low red blood cells) after a stem cell transplant in people with blood cancers and a bone marrow condition called myelofibrosis. About 196 adults will receive either luspatercept or standard supportive care…
Matched conditions: MYELOFIBROSIS (MF)
Phase: PHASE2, PHASE3 • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Can patients stop Anti-Rejection drugs sooner after transplant?
Disease control Not yet recruitingThis study tests whether patients can safely stop the drug tacrolimus earlier than usual after a stem cell transplant. Tacrolimus is given to prevent graft-versus-host disease (GVHD), but newer methods have lowered GVHD risk. The trial will enroll 50 people with blood cancers and…
Matched conditions: MYELOFIBROSIS (MF)
Phase: PHASE1 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New drug ZE74-0282 targets rare blood cancers in early trial
Disease control Not yet recruitingThis early-phase study tests an experimental drug, ZE74-0282, in about 60 adults with polycythemia vera or myelofibrosis caused by a specific JAK2 gene mutation. The main goals are to find a safe dose and check for side effects, while also seeing if the drug shows signs of fighti…
Matched conditions: MYELOFIBROSIS (MF)
Phase: PHASE1 • Sponsor: Eilean Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Head-to-Head: which JAK inhibitor wins for myelofibrosis patients with low blood counts?
Disease control Not yet recruitingThis study compares two FDA-approved drugs, momelotinib and ruxolitinib, in people with myelofibrosis who also have low blood cell counts. The main goal is to see which drug does a better job at shrinking the spleen and reducing the need for blood transfusions. About 268 particip…
Matched conditions: MYELOFIBROSIS (MF)
Phase: PHASE4 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New drug combo may boost stem cell success in rare bone marrow cancer
Disease control Not yet recruitingThis study tests whether the drug gecacitinib, given before, during, and after a stem cell transplant, can help people with myelofibrosis (a type of bone marrow cancer) have better outcomes. About 39 adults aged 18-75 with intermediate- or high-risk myelofibrosis will take part. …
Matched conditions: MYELOFIBROSIS (MF)
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Momelotinib under the microscope: Real-World spleen shrinkage in myelofibrosis
Knowledge-focused Not yet recruitingThis study will observe 93 adults with myelofibrosis who are taking momelotinib as part of their normal care. Researchers will track how well the drug reduces spleen size after 6 months, providing real-world evidence of its effectiveness.
Matched conditions: MYELOFIBROSIS (MF)
Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC